Lunit vs Shukun 数坤科技
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Lunit
KOSDAQ-listed Korean AI for breast and chest cancer screening
Visit
|
Shukun 数坤科技
Beijing imaging AI with China's most Class III approvals, by its own c...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 6.7 / 10 | 6.8 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Enterprise | Enterprise |
| Free tier | — | — |
| Paid from | No public $ price — quoted per institution via Lunit sales and imaging partners | Quoted on request (hospital and distributor sales, trial by application) |
| Has API | ✗ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | — | — |
| Founded | 2015 | 2017 |
| Maker | — | — |
| Verdict | Lunit is one of the few medical-AI vendors with substantial revenue behind it: KRW 45.8 billion in the first half of 2026, up 23%, almost all earned abroad, though it is still loss-making and completed a KRW 211.5 billio... |
Shukun's case rests on approvals and breadth: 18 Chinese Class III certificates by its count, MDR CE marks across cardiac, stroke and other tools, PMDA approvals in Japan and three FDA 510(k) clearances, including Corona... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.